Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
Epistemonikos ID: 08afc5e884a054a3f292ad87328a71a9c386101a
First added on: May 21, 2024